Vertex Shares Rise on Telaprevir Outlook - Forbes.com: "NEW YORK -
Vertex Pharmaceuticals Inc. shares jumped Wednesday as Wall Street kept a positive outlook on the company's developing hepatitis C drug, despite a wider second-quarter loss.
The stock gained $2.64, or 8.9 percent, to reach $32.36 in afternoon trading. Shares have traded between $25.61 and $45.38 over the last 52 weeks."
